NAD Clinical Trials: What Randomized Human Studies Have Measured

In plain English

When people search NAD clinical trials, they usually want one thing: has this been tested in humans, and did it do anything? Short answer: the precursors NMN and NR (the building blocks the body turns into NAD+) have been through several randomized, placebo-controlled human trials, and they reliably raised the amount of NAD+ in blood. Some trials also measured real-world things like walking distance and insulin sensitivity, with modest improvements. What the trials have not yet shown is that any of this prevents disease or extends lifespan in people. This page lays out those studies, tier by tier, and cites each one.

The NMN human trials

Two NMN trials anchor the human evidence. In a randomized trial in prediabetic, postmenopausal women, 250 mg/day of oral NMN for 10 weeks significantly increased muscle insulin sensitivity by hyperinsulinemic-euglycemic clamp and remodeled insulin signaling, with no change in body composition or HbA1c ^[1]. In a randomized, multicenter, double-blind, placebo-controlled, dose-dependent trial in healthy middle-aged adults, NMN at 300, 600, or 900 mg/day for 60 days raised blood NAD+ at days 30 and 60 across all groups versus placebo (p ≤ 0.001), improved walking distance and quality-of-life scores, did not raise a biological-age measure, and flagged 600 mg/day as optimal — with no safety issues at any dose ^[3]. The multicenter design strengthens generalizability beyond a single site.

The NR dose-ranging trial

The clearest dose-response in the human record comes from NR. In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, NR at 100, 300, and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51%, and 142% respectively, an elevation maintained throughout the study, with no flushing and no significant adverse-event differences from placebo ^[4]. NR did not elevate LDL cholesterol or disrupt one-carbon metabolism ^[4]. A separate 14-day randomized trial confirmed both NR and NMN raise whole-blood NAD+ roughly 2-fold versus placebo, while nicotinamide did not ^[13].

Pooled and rare-disease evidence

Beyond single trials, a 2024 systematic review of 10 randomized controlled trials (n = 437, mean age 58) found NMN supplementation produced statistically significant improvements in gait speed, sit-to-stand performance, 6-minute walking distance, and SF-36 quality-of-life scores ^[15]. In rare DNA-repair diseases, a review reported promising results: a 52-week NR trial in Werner syndrome (n = 9) produced a ~140% plasma NAD+ increase with improved arterial stiffness, HDL counts, and kidney function, and 4-month and 2-year trials in ataxia-telangiectasia showed improved ataxia scores and slower neuromotor decline ^[11]. These are small or single-condition studies; they describe what was measured in specific populations, not a general treatment claim.

What the trials actually measured: whole-blood NAD+

Almost every NAD+ precursor trial reports the same primary readout: whole-blood NAD+. The reason is practical — directly sampling tissue NAD+ in living humans is invasive and rare, so blood NAD+ is the standard pharmacodynamic marker that a precursor reached the body and was converted ^[13]. That makes the human evidence base unusually consistent on one point and unusually thin on another. It is consistent that oral NR and NMN raise circulating NAD+ in a dose-dependent way: NR at 22/51/142% across 100/300/1000 mg/day ^[4], NMN dose-dependently across 300-900 mg/day ^[3], and both roughly 2-fold versus placebo in a 14-day head-to-head ^[13].

What blood NAD+ does not tell you is what happened inside specific tissues, or whether a downstream clinical endpoint moved. A 2025 review noted that tissue-specific NAD+ data in humans remain sparse ^[10]. So a trial can confidently report that a precursor raised the marker while leaving open whether that translated into a meaningful change in muscle, brain, or any organ. Reading the NAD clinical trials honestly means holding those two facts together: the marker reliably moves, and the tissue-and-outcome picture is still being filled in.

The limits of the human evidence

The honest boundary of the NAD clinical trials record is this: raising blood NAD+ with precursors is well demonstrated, but translation to hard clinical outcomes — longevity, disease prevention — remains unproven in humans. A 2025 Nature Metabolism review of NAD+ precursor supplementation in ageing concluded that human trials have shown limited efficacy, that age-related NAD+ decline has been consistently observed in only a limited number of human studies, and that tissue-specific NAD+ data remain sparse, underscoring the need for more clinical studies rather than reliance on rodent extrapolation ^[10]. The trials measured blood levels and some functional endpoints; they did not establish NAD+ or its precursors as a treatment for any disease.

Does NAD make you look younger?

No study in this record shows NAD+ or its precursors make people look younger. The strongest anti-aging data are rodent, and the 2025 Nature Metabolism review judged human efficacy for hard endpoints preliminary ^[10]. No cited human trial measured appearance as an endpoint.